News Conference News ESC Heart Failure 2022 HF Triple Therapy Doesn’t Seem Effective in True Preserved HF Shelley Wood May 25, 2022
News Conference News ESC Heart Failure 2022 Sweet Spot for Omecamtiv Mecarbil in HFrEF May Lie in Low SBP Patients Shelley Wood May 23, 2022
News Conference News ESC Heart Failure 2022 Dapagliflozin Boosts Health Status Across LVEF Range Shelley Wood May 23, 2022
News Conference News ESC Heart Failure 2022 Speech-Recognition Tool May Predict Worsening Congestion in HF Shelley Wood May 22, 2022
News Conference News EuroPCR 2022 MitraClip ‘Bridge’ Strategy Continues to Help Sickest HF Patients Michael O'Riordan May 20, 2022
News Conference News EuroPCR 2022 MitraClip Helps for Atrial Functional MR: MITRA-TUNE Michael O'Riordan May 19, 2022
News Conference News HRS 2022 Gains in HF Drug Therapy Raise Questions About ICD Benefit in Modern Era Todd Neale May 02, 2022
News Conference News ACC 2022 DIAMOND Shines Bright on Patiromer for Curbing Hyperkalemia in HFrEF L.A. McKeown April 08, 2022
News Conference News ACC 2022 METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF Todd Neale April 08, 2022
News Conference News ACC 2022 QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis L.A. McKeown April 07, 2022
News Conference News ACC 2022 PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization L.A. McKeown April 03, 2022
News Conference News ACC 2022 Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term Shelley Wood April 03, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Conference News THT 2022 Probe Beyond Ejection Fraction to Understand and Manage HFpEF L.A. McKeown February 07, 2022
News Conference News STS 2022 Tricuspid Repair During Mitral Valve Surgery Prevents TR Progression Michael O'Riordan February 04, 2022
News Conference News STS 2022 Modified Surgical MV Repair Stands Up to Replacement Michael O'Riordan February 03, 2022
News Conference News AHA 2021 Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF Michael O'Riordan November 19, 2021
News Conference News AHA 2021 Empagliflozin Retains Benefits in ‘True’ HFpEF Patients Todd Neale November 17, 2021
News Conference News AHA 2021 Canagliflozin Improves Quality of Life in HF Patients Michael O'Riordan November 16, 2021
News Conference News AHA 2021 Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE Shelley Wood November 14, 2021